BPC-157 capsules vs injection: what the studies actually used

Type BPC-157 into a UK search engine and the suggestions are dominated by one comparison: capsules against injection, tablets against vials, oral against subcutaneous. The question people are really asking is whether a peptide that was studied in rats by injection does anything when it is swallowed in a capsule. This article does not answer that with a verdict, because the literature does not contain one. Instead it lays out which routes the studies used, what the pharmacokinetic data say, and what that means for anyone comparing formats. For the broader picture of what the compound is and what the research shows, read the companion article on what the BPC-157 research actually shows. Free Muscle sells BPC-157 and its own-brand BPC-150 for laboratory research only, to adults, and nothing here is guidance on taking either.

What BPC-157 is, briefly

BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. Its developers describe it as a partial sequence of a protein found in human gastric juice, which they named body protection compound, and it was investigated under the code PL 14736 for inflammatory bowel disease. Almost all of the published work comes from a single research group at the University of Zagreb and covers rodent models of gut, tendon, ligament, muscle and vascular injury. It has never been licensed as a medicine in any country. A 2019 independent review concluded that the rodent findings were consistently positive but that efficacy had not been confirmed in humans and that only a handful of groups had studied the peptide in depth (Gwyer 2019).

Which routes the studies actually used

This is the part most listings skip. The Zagreb group has, unusually, tested BPC-157 by several routes side by side within the same experiments, and the details matter.

Intraperitoneal injection

The most common route in the rat work is intraperitoneal injection, meaning into the abdominal cavity, with the group typically comparing a microgram-per-kilogram and a nanogram-per-kilogram regimen in the same experiment. This is a laboratory route, not one used in people, and it delivers the peptide to the portal circulation and the peritoneal tissues rather than into a muscle or under the skin. When a website cites a rat study to support an injectable product, it is usually citing an intraperitoneal study.

Per-oral in drinking water

In a 2010 study of medial collateral ligament transection in rats, BPC-157 was given in three ways: by intraperitoneal injection, per-orally dissolved in the drinking water, and as a thin layer of cream at the injury site. The authors reported functional, biomechanical, macroscopic and histological healing improvements with each route (Cerovecki 2010). A 2011 study of diclofenac toxicity in rats reported that BPC-157 was strongly effective against diclofenac-induced gastric, intestinal, liver and brain lesions whether it was injected intraperitoneally or given in the drinking water (Ilic 2011). So the oral route does have rat data behind it, and that is the honest basis for the claim that BPC-157 is "orally active".

Three caveats apply. First, the peptide in these studies was in continuous dilute solution sipped throughout the day, not a single bolus in a capsule. Second, the gut and the liver were often the target tissue, and a peptide swallowed by a rat reaches its own gut lining directly, without needing to survive absorption. Third, the group's own explanation for oral activity is that BPC-157 is unusually stable in gastric juice, a property they report from their own laboratory and which has not been independently replicated in a published human study.

Topical, intragastric and other routes

The same ligament study used a thin layer of cream at the injury site. Other papers from the group use intragastric administration by tube, local injection into the injured muscle and, in eye models, drops. This range is why the group argues the peptide is active by almost any route. A compound reported as active by every route, at regimens spanning three orders of magnitude from nanograms to micrograms per kilogram, has an unusual pharmacological profile, and one that would normally need confirmation by independent laboratories before much weight is placed on it.

What the pharmacokinetic data show

Until 2022 there was no published pharmacokinetic study of BPC-157 at all. A Chinese group preparing the peptide for clinical development then reported its behaviour in rats and beagle dogs. After intravenous and intramuscular administration the elimination half-life of the intact peptide was under 30 minutes in both species. Absolute bioavailability after intramuscular injection was around 14 to 19 percent in rats and 45 to 51 percent in dogs. Using tritium-labelled peptide, the authors showed that BPC-157 was rapidly broken into small fragments and then into single amino acids that entered normal amino acid metabolism, with excretion mainly in urine and bile (He 2022).

Two things follow. The intact peptide does not persist in blood for long even when injected. And the study did not test the oral route, so there is still no published measurement of how much intact BPC-157, if any, reaches the bloodstream after a capsule is swallowed in any species, so any oral bioavailability percentage quoted for capsules is not drawn from the peer-reviewed literature.

Why peptides by mouth are a problem in general

Peptides are chains of amino acids joined by peptide bonds, and the digestive system exists to break peptide bonds. Pepsin in the stomach and trypsin, chymotrypsin and the brush-border peptidases of the small intestine dismantle dietary protein into fragments of two or three residues and single amino acids before absorption. A 15-residue peptide is a small protein as far as those enzymes are concerned. The few peptide medicines that are given by mouth rely on specially engineered formulations with absorption enhancers, and even then only a small fraction of the dose reaches the bloodstream. The general problem is set out in the article on whether oral peptides work. BPC-157's developers claim it is an exception because of its stability in gastric juice; that claim rests on their rat data and has not been tested in a published human pharmacokinetic study.

What human data exist

Very little. A 2021 retrospective chart review from a private clinic in Florida described 16 patients who had received intra-articular knee injections of BPC-157, some combined with thymosin beta-4, and reported by telephone survey that 14 had relief of knee pain. There was no control group and no blinding, and the authors state that no specific tools were used to measure function or quality of life (Lee 2021). It is one of very few published human reports, and it used injection into the joint, not capsules. Earlier inflammatory bowel disease trials under the PL 14736 code are referred to in the Zagreb group's papers but their results have not been published in a form that can be checked. No controlled human trial of oral BPC-157 exists.

Adverse findings and limitations

An independent review noted that few studies had reported adverse reactions (Gwyer 2019), but absence of adverse findings in small animal experiments designed to detect healing is not a safety profile. There are no human toxicology data in the public domain. The peptide's proposed actions on blood vessel growth and on nitric oxide signalling are exactly the kind of systemic effects that would need a controlled human trial to characterise. The concentration of the evidence in one laboratory, and the very wide range of effective regimens reported, are further limitations. None of this is a claim about any product on this site.

Regulatory status

United Kingdom

BPC-157 is not a licensed medicine and the MHRA has not granted any marketing authorisation for it. It is not an authorised food supplement or novel food, so it cannot lawfully be sold as something to eat. It can be sold to adults for laboratory research provided it is not presented for human consumption. It is not a controlled drug. That is the basis on which the brands on the BPC-157 collection page and the Free Muscle BPC-150 are offered.

European Union and United States

No marketing authorisation exists from the EMA or any EU national agency. In the United States it has never been approved by the FDA, and in 2023 the FDA placed BPC-157 in category 2 of its list of bulk drug substances nominated for compounding, the category for substances it has identified as potentially presenting significant safety risks. That list is reviewed from time to time, but BPC-157 has never been an approved medicine in the United States.

WADA

BPC-157 is named on the WADA Prohibited List under class S0, non-approved substances, which covers any pharmacological substance with no current approval for human therapeutic use by any governmental regulatory health authority. S0 is prohibited at all times. Anti-doping laboratories have had a validated urine method since 2017, when the United States anti-doping laboratory in Salt Lake City identified BPC-157 in confiscated vials and developed an assay with a detection limit of 0.1 nanograms per millilitre, noting that the peptide forms a stable metabolite and remained stable in urine for at least four days (Cox 2017). A detection window after administration has not been published, so the accurate statement is that it is detectable and the window is not established.

Common questions

BPC-157 capsules vs injection: which is better?

The literature cannot answer this. Rat studies report activity by both routes; the only pharmacokinetic study tested injection but not oral; and there is no controlled human trial by any route. Free Muscle sells capsule products for laboratory research and does not advise on formats for any other purpose.

Is BPC-157 legal in the UK?

BPC-157 is not a controlled drug in the UK, and it is sold to adults as a laboratory research material. It is not a licensed medicine or an authorised food supplement, so it cannot be sold for human consumption. It is prohibited at all times in sport under WADA class S0.

BPC-157 and the NHS

The NHS does not prescribe BPC-157, because no licensed medicine containing it exists in the UK or anywhere else. Research-grade material is not a medicine and is not supplied for prescription.

BPC-157 and TB-500 together

The two are unrelated molecules, both unlicensed. We do not publish combination or dosing guidance for research compounds. The TB-500 collection page covers the other peptide and lists the brands stocked.

BPC-157 dosage, side effects, benefits, before and after

We do not publish dosing, cycle or outcome claims for any research compound. What the studies measured is summarised above, in rats, by the routes described. No systematic human safety data exist. Anyone with a medical question should speak to a doctor.

BPC-157 capsules UK reviews

Customer reviews cannot tell you what a capsule contains. A certificate of analysis for the batch can. The section below explains what to look for.

What is BPC-150?

BPC-150 is the name of Free Muscle's own-brand capsule product, sold as a variant of BPC-157. The name BPC-150 does not appear in the published literature (a PubMed search for it returns no records), so the studies discussed here are all studies of BPC-157. Every Free Muscle-brand batch is assayed by Janoshik Analytical and the certificate for a batch is sent on request by email.

How to verify a batch

Because the product is unregulated, the label is a claim until a laboratory has checked it. For a peptide capsule, a meaningful certificate of analysis states the batch number printed on the pack, an identity test (HPLC or LC-MS confirming the expected molecular mass of BPC-157, about 1419 daltons), a purity percentage for the peptide, the quantity per capsule where tested, the laboratory's name and the date. A certificate for the raw powder from the manufacturer's supplier is not a certificate for the finished capsules; a PDF with no batch number is not a certificate for anything.

  • Free Muscle brand (BPC-150): Janoshik Analytical assays every batch; email to request the certificate for the batch number on your pack.
  • Other brands stocked: a certificate is shown only where the manufacturer supplies one for the batch held. Where there is none, the label has not been independently verified.
  • Compare: total milligrams per pack and the tested purity, not the marketing. The article on price per milligram shows the arithmetic.

See how to read a certificate of analysis, what Janoshik Analytical is, and the lab tests page for how to request one.

Related reading

BPC-157 and BPC-150 are sold by Free Muscle for laboratory research only. They are not licensed medicines, have not been evaluated by the MHRA, EMA or FDA, are not food supplements and are not for human consumption. Customers must be 18 or over. Nothing in this article is medical, dosing or usage advice, and the studies described do not support any claim about any product.

References

  1. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319.
  2. Ilic S, Drmic D, Franjic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011;88(11-12):535-542. PMID: 21295044.
  3. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID: 36588717.
  4. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550.
  5. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.
  6. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. PMID: 28035768.